Inhibitors of human tumor-expressed CCXCKR2
2 Assignments
0 Petitions
Accused Products
Abstract
Pharmaceutical compositions containing organic compounds or salts thereof that serve as modulators for the SDF-1 or I-TAC chemokines are disclosed. The compounds and compositions are useful in the treatment of cancer, especially in the inhibition of cancer proliferation, growth, and metastasis. Methods of interfering with SDF-1 and/or I-TAC binding to the CCXCKR2 receptor and treating cancer using the compounds and pharmaceutical compositions of the present invention are also disclosed.
-
Citations
38 Claims
- 1. A modulator of the structure (I), or a salt thereof:
- 27. A modulator having the structure (II):
-
30. A modulator comprising one of the following formulae:
-
33. A pharmaceutical composition comprising the modulator of claim and a pharmaceutically acceptable carrier.
-
34. A pharmaceutical composition comprising a compound of the formulae:
-
35. A method of inhibiting the binding of chemokines I-TAC and/or SDF-1 to a CCXCKR2 receptor, comprising contacting the composition of claim 3234 with a cell that expresses the CCXCKR2 receptor for a time sufficient to inhibit the binding of the chemokines to the CCXCKR2 receptor.
-
37. A method of treating cancer, comprising administering a therapeutically effective amount of the composition of claim 3234 to a cancer patient for a time sufficient to treat the cancer.
Specification